Showing results (331-340 of 475) with videos related to
Sort By:
Pageof 48
NPJ Precision Oncology|April 6, 2025
The single-cell spatial landscape of stage III colorectal cancersAndrew Su, HoJoon Lee, Minh Tran, et al.Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1Kok Choi Kong, Adrian J Butcher, Phillip McWilliams, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 22, 2014
Rationale, development, implementation, and initial results of a fast track protocol for transfemoral transcatheter aortic valve replacement (TAVR)Rebecca Marcantuono, Jacob Gutsche, Maureen Burke-Julien, et al.Genome Research|October 14, 2011
Estimation of rearrangement phylogeny for cancer genomesChris D Greenman, Erin D Pleasance, Scott Newman, et al.Current Problems in Cardiology|June 23, 2024
Outcomes of Ultrafiltration in community-based hospitalsViswanath R Chinta, Neelima P Theella, Joel M Raja, et al.FEMS Microbiology Letters|November 13, 2020
High-density transposon libraries utilising outward-oriented promoters identify mechanisms of action and resistance to antimicrobialsChris Coward, Gopujara Dharmalingham, Omar Abdulle, et al.Hepatology Communications|March 13, 2019
A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary CholangitisMarlyn J Mayo, Paul J Pockros, David Jones, et al.Mabs|February 9, 2016
Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesKathryn Chapman, Akosua Adjei, Paul Baldrick, et al.Biotechnology Progress|February 8, 2003
High-level expression of recombinant IgG in the human cell line per.c6David Jones, Nathalie Kroos, Regina Anema, et al.Journal of Pharmacological and Toxicological Methods|September 1, 2020
Is there a role for the no observed adverse effect level in safety pharmacology?Tomas Mow, Ninette K Andersen, Nils Dragsted, et al.Pageof 48